Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Ankylosing spondylitis (AS) is a common immune-mediated inflammatory arthritis with a strong genetic predisposition. We review recent data from genetic and animal studies highlighting the importance of Type 17 immune responses. Furthermore, the efficacy (or lack thereof) of different anti-cytokine monoclonal antibodies has highlighted the diversity of Type 17 immune cells and cytokines critical to AS and related spondyloarthritis pathogenesis. Recent studies have strongly implicated the gut microbiome in AS. Finally, we propose that the local metabolic environment of the joint may have a key role in driving AS, and present a novel model of AS pathogenesis.

More information Original publication

DOI

10.1111/imm.13242

Type

Journal article

Publication Date

2020-10-01T00:00:00+00:00

Volume

161

Pages

94 - 102

Total pages

8

Keywords

ankylosing spondylitis, immunometabolism, microbiome, spondyloarthritis, Animals, Gastrointestinal Microbiome, Humans, Inflammation, Spondylitis, Ankylosing, Th17 Cells